Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 10mg | $42.99 | $4.30/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 1672 | Mar 2026 | 99.0% | Vanguard Laboratory | Endotoxin, Sterility, Heavy metals | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHRP-2 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Peptidology sell GHRP-2?
Yes — Peptidology currently lists GHRP-2 in 1 variant starting at $42.99 ($4.30/mg).
Is Peptidology's GHRP-2 third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Peptidology's GHRP-2, with the most recent showing 99.0% purity. Peptidology holds an overall trust grade of B (88/100) across all 162 COAs on file.
What is Peptidology's trust grade for GHRP-2?
Peptidology has an overall Disclosed Labs trust grade of B (88/100), computed from 162 COAs across all peptides. The most recent GHRP-2 COA was issued by Vanguard Laboratory.
Where is the cheapest GHRP-2?
As of the latest data, Verified Peptides offers GHRP-2 at $1.62/mg — compare with Peptidology's listing at $4.30/mg. See the full GHRP-2 price comparison.
Is GHRP-2 legal to buy?
GHRP-2 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs